{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:04:55Z","timestamp":1784005495096,"version":"3.55.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Pathological subtype transformations may occur during the targeted therapy for lung adenocarcinoma. Among these, transformation to pulmonary giant cell carcinoma (PGCC) is rare, but clinically significant. This paper reports the case of a 71-year-old male patient with lung adenocarcinoma harboring the\n                    <jats:italic>KRAS G12C<\/jats:italic>\n                    mutation who developed resistance to sotorasib-targeted therapy, and subsequent re-biopsy confirmed transformation to PGCC. Combined with a literature review, the possible mechanisms of this transformation and its clinical implications were analyzed, emphasizing the importance of re-biopsy after targeted therapy resistance to guide subsequent treatment and provide a reference for the diagnosis and treatment of similar cases.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1846681","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:21:50Z","timestamp":1784002910000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Transformation from lung adenocarcinoma to pulmonary giant cell carcinoma following targeted therapy: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Shicheng","family":"Yuan","sequence":"first","affiliation":[{"name":"Department of the Second Clinical Medical College, Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, the Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, the Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfeng","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, the Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, the Second Hospital of Jilin University","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"B1","volume-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","year":"2015"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/LCTT.S186779","article-title":"Approaches to tumor classification in pulmonary sarcomatoid carcinoma","volume":"10","author":"Baldovini","year":"2019","journal-title":"Lung Cancer Targets Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28749","article-title":"US lung cancer trends by histologic type","volume":"120","author":"Lewis","year":"2014","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S150124","article-title":"Molecular features of giant-cell carcinoma of the lung: a case report and literature review","volume":"11","author":"Li","year":"2018","journal-title":"OncoTargets Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jtho.2018.12.005","article-title":"Best practices recommendations for diagnostic immunohistochemistry in lung cancer","volume":"14","author":"Yatabe","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/crj.13586","article-title":"Clinicopathological features and prognostic nomogram of giant cell carcinoma of the lung: a population\u2010based study","volume":"17","author":"He","year":"2023","journal-title":"Clin Respir J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13850","article-title":"Pulmonary large cell carcinoma, highly positive for PD\u2010L1, shows marked response to pembrolizumab: a case report","volume":"12","author":"Okabe","year":"2021","journal-title":"Thorac Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2023.107293","article-title":"KRAS G12C in advanced NSCLC: prevalence, co-mutations, and testing","volume":"184","author":"Lim","year":"2023","journal-title":"Lung Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251369038","article-title":"Histologic transformation after targeted therapy resistance in driver gene-positive NSCLC: mechanisms and therapeutic challenges","volume":"17","author":"Li","year":""},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000001205","article-title":"Small cell lung cancer transdifferentiation: not a negligible phenomenon","author":"Horvath","year":"2025","journal-title":"Curr Opin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0289","article-title":"Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinoma","volume":"14","author":"Li","year":"2024","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2499","article-title":"Cancer stem cells in solid tumours: accumulating evidence and unresolved questions","volume":"8","author":"Visvader","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/crj.13705","article-title":"Study on the application of percutaneous closed pleural brushing combined with cell block technique in the diagnosis of Malignant pleural effusion","volume":"18","author":"Wang","year":"2024","journal-title":"Clin Respir J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1618672","article-title":"Long-term survival in advanced pulmonary large-cell neuroendocrine carcinoma after multi-line immunochemotherapy and anti-angiogenic therapy: a case report","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1846681\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:21:51Z","timestamp":1784002911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1846681\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":16,"alternative-id":["10.3389\/fonc.2026.1846681"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1846681","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"article-number":"1846681"}}